Liberum Capital restated their buy rating on shares of PureTech Health (LON:PRTC) in a research report report published on Thursday morning, ThisIsMoney.Co.Uk reports.
Several other analysts also recently commented on the stock. Jefferies Financial Group raised their target price on shares of PureTech Health from GBX 280 ($3.66) to GBX 340 ($4.44) and gave the stock a buy rating in a report on Friday, July 5th. Peel Hunt restated a buy rating on shares of Costain Group in a report on Friday, June 28th.
Shares of PRTC stock opened at GBX 240 ($3.14) on Thursday. The company has a quick ratio of 0.95, a current ratio of 0.98 and a debt-to-equity ratio of 7.19. The firm has a market cap of $677.99 million and a P/E ratio of -15.00. The business’s 50 day moving average is GBX 223.52. PureTech Health has a 52 week low of GBX 135 ($1.76) and a 52 week high of GBX 239 ($3.12).
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.